Insights from 2023 ASCO® Annual Meeting


 

ASCO® 2023 Insights: "Pirtobrutinib in cBTKi Pre-Treated MCL - Updated Results & Subgroup Analysis From the Phase 1/2 BRUIN Study With 2 Years of Survival Follow-Up"

247 views
June 14, 2023
Comments 0
Login to view comments. Click here to Login